In the study of kidney diseases, TMAO often induces kidney dysfunction and a decrease in glomerular filtration rate through pathways like activating autophagy, inducing inflammation, promoting renal interstitial fibrosis, inducing apoptosis, and oxidative stress
References [1] Li, F., Li, S., Shi, Y., Lin, F., Rui, L., Shi, J
Estrogen decline in midlife can change how the body experiences a GLP-1 dose
Table 11: Results at Week 24 (LOCF*) in an Active-Controlled Trial of Dapagliflozin Initial Combination Therapy with Metformin HCl Extended-Release in Adults with Type 2 Diabetes Mellitus Figure 2: Adjusted Mean Change from Baseline Over Time in HbA1c (%) in a 24-Week Active-Controlled Trial of Dapagliflozin Initial Combination Therapy with Metformin HCl Extended-Release in Adults with Type 2 Diabetes Mellitus In the second trial (NCT00643851), 603 patients were randomized to 1 of 3 treatment arms following a 1-week lead-in period: dapagliflozin 5 mg plus metformin HCl extended-release (up to 2,000 mg/day), dapagliflozin 5 mg plus placebo, or metformin HCl extended-release (up to 2,000 mg/day) plus placebo
